FDA approves daraxonrasib, a once-daily pill for advanced pancreatic cancer
Science & ClimateWell-covered
|
The Facts
- The FDA on Wednesday approved daraxonrasib, sold under the brand name Rasonque by Revolution Medicines.
- The approval covers adults with metastatic pancreatic adenocarcinoma who had prior systemic therapy or cannot receive combination chemotherapy.
- Daraxonrasib is a once-daily oral pill designed to block multiple forms of the RAS protein, which drives tumor growth.
- In a 500-patient trial, median overall survival was 13.2 months on the drug versus about 6.7 months on chemotherapy.
- More than 90% of pancreatic cancers carry mutations in KRAS, the gene behind the proteins the drug targets.
- Pancreatic cancer has a five-year survival rate of about 13% in the US, according to the American Cancer Society.
- Revolution Medicines said a one-month supply of the drug will cost approximately $39,800.
- The approval does not cover first-line treatment, which drug developers describe as the pancreatic cancer field's next priority.
Context
How does the drug work, and why was this target hard to hit?
Daraxonrasib blocks several active forms of the RAS protein, which relays signals that help cancer cells grow and survive CNBC,India Today. RAS proteins are produced by the KRAS gene, mutated in more than 90% of pancreatic cancers, and long resisted conventional drug development BBC,Hürriyet,Newsweek. MD Anderson trial investigator Shubham Pant has compared KRAS to "a shiny ball" Newsweek.
How fast did the FDA act, and what did it say?
The FDA granted expedited approval Aol,Guardian,India Today and said it acted more than six months ahead of its review deadline Fox News. The agency said the drug provides "a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer" BBC,Fox News.
What will it cost patients?
Revolution Medicines put the price at roughly $39,800 for a one-month supply Aol,Hindustan Times. Hindustan Times reports that works out to about $475,000 a year Hindustan Times. The pill is now available by prescription in the United States Newsweek.
Where Left and Right agree, and where they split
- Where Left and Right agree
- Doubling median survival from about 6.7 to 13.2 months in a cancer where roughly 13% reach five years is a real gain, and those months are what both treat as the stake.
- Where Left and Right split
- A $39,800 monthly price deciding which eligible patients get the extra months, or protecting the incentive that produced those months at all.
- Why they won’t converge
- This is a values divide about who owns the gains from risk: the same survival curve and the same $39,800 price read as a rationing filter or as the earned return on a decades-failed bet, so more data cannot settle it.
How left and right read it
Time bought by public science should not be sold back at $39,800 a month. Because daraxonrasib roughly doubles median survival — 13.2 months against about 6.7 on chemotherapy — in a disease with a five-year survival rate near 13%, that monthly price is not a market signal but a filter deciding who gets the extra months. The breakthrough is real. So the question is what public negotiation or compulsory pricing action is required before a single eligible patient is priced out?
“The new drug can double survival time for a cancer that was once considered hopeless.” — CBS News
The thing worth protecting here is whatever incentive persuaded a company to chase a target sitting in more than 90% of pancreatic cancers, in a disease where about 13% of patients reach five years. That gamble produced a once-daily pill with median survival of 13.2 months against roughly 6.7 on chemotherapy, and a public face — a former senator who told the country what taking it was like. Reward the risk that bought those months.
“Manufactured by Revolution Medicines, daraxonrasib made headline earlier this year when former US Sen. Ben Sasse, R-Neb., shared details about his experience with the drug” — New York Post
The receipts — 100 sources
Wire services (4)
Independent coverage (96)
The news, read by both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.